Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit

Expected with high hopes by all those affected by Alzheimer's and investors alike, the Phase 3 trial of Cassava Sciences' proprietary small molecule Simufilam failed to deliver the anticipated results.…

Continue Reading Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit

The Most Relaxing Switch JRPGs

JRPGs are some of the most engaging titles available to players today, often involving immersive stories and great, well-constructed gameplay mechanics. These games are ones that players can lose themselves…

Continue Reading The Most Relaxing Switch JRPGs